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Divergent Annexin A1 expression 
in periphery and gut is associated 
with systemic immune activation 
and impaired gut immune response 
during SIV infection
Angela A. S. Sena1,2, Tiffany Glavan2, Guochun Jiang2, Sumathi Sankaran-Walters2, 
Irina Grishina2, Satya Dandekar2 & Luiz R. Goulart1,2
HIV-1 disease progression is paradoxically characterized by systemic chronic immune activation and 
gut mucosal immune dysfunction, which is not fully defined. Annexin A1 (ANXA1), an inflammation 
modulator, is a potential link between systemic inflammation and gut immune dysfunction during the 
simian immunodeficiency virus (SIV) infection. Gene expression of ANXA1 and cytokines were assessed 
in therapy-naïve rhesus macaques during early and chronic stages of SIV infection and compared 
with SIV-negative controls. ANXA1 expression was suppressed in the gut but systemically increased 
during early infection. Conversely, ANXA1 expression increased in both compartments during chronic 
infection. ANXA1 expression in peripheral blood was positively correlated with HLA-DR+CD4+ and 
CD8+ T-cell frequencies, and negatively associated with the expression of pro-inflammatory cytokines 
and CCR5. In contrast, the gut mucosa presented an anergic cytokine profile in relation to ANXA1 
expression. In vitro stimulations with ANXA1 peptide resulted in decreased inflammatory response 
in PBMC but increased activation of gut lymphocytes. Our findings suggest that ANXA1 signaling 
is dysfunctional in SIV infection, and may contribute to chronic inflammation in periphery and with 
immune dysfunction in the gut mucosa. Thus, ANXA1 signaling may be a novel therapeutic target for 
the resolution of immune dysfunction in HIV infection.
Human immunodeficiency virus (HIV) infection causes progressive loss of CD4+ T cells in peripheral blood1 
and systemic chronic immune activation leading to AIDS2. In contrast, the virus causes massive loss of CD4+ 
T cells and immune dysfunction in the gut mucosa leading to the gut barrier disruption and microbial translo-
cation3. The gut tissue damage is correlated with HIV progression4. Most investigations in HIV research have 
focused on the mediators of inflammation while regulation and role of anti-inflammatory molecules in HIV 
pathogenesis has been understudied. Our understanding is limited about molecular networks or specific path-
ways that may establish a link between the systemic immune activation and gut immune anergy in HIV infection 
and explain discordance between these two compartments.
We previously found that gene expression of Annexin A1 (ANXA1), an anti-inflammatory molecule was dif-
ferentially regulated in the gut of therapy-naïve simian immunodeficiency virus (SIV) infected rhesus macaques, 
an established non-human primate model of AIDS5. ANXA1 is a 37 KDa protein known to be a downstream 
mediator of glucocorticoids, and a highly active mediator of rapid resolution of inflammation6–9. ANXA1 expres-
sion is associated with several inflammatory diseases and autoimmune diseases10. However, its role in infectious 
diseases and specifically, in HIV infection is under-investigated. ANXA1-deficient mice showed increased sus-
ceptibility to Mycobacterium tuberculosis, which was attributed to an impaired dendritic cell efferocytosis and 
cross-presentation of antigens to pathogen specific CD8+ T cells11. The ANXA1 has potential to regulate and link 
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pathways of systemic immune activation while influencing pathways immune anergy in the gut mucosa during 
inflammatory diseases. Thus, it could potentially contribute to the discordant immune responses between the 
gut and peripheral blood compartments in HIV infection. Immune activation in HIV and SIV infections is well 
characterized by an increased expression of known pro-inflammatory markers (TNF-α , IL-6, IL-1β , MIP-1α , 
MIP-1β and RANTES) in the activated phenotypes of CD4+ and CD8+ T cells, B, NK and monocytes12. The 
gut mucosal disruption in SIV and HIV infections leads to immunological anergy at the mucosal site13–15. The 
ANXA1 has potential to impact this at several levels. First, ANXA1 may function as an anti-inflammatory pro-
tein during the acute inflammatory HIV infection, and also exert an immediate inhibitory action on neutrophil 
migration and monocyte/macrophage and mast cell-mediators production16. Second, ANXA1 has been reported 
to regulate mucosal inflammation, including oral17, nasal18, lung19 and gastrointestinal20,21 mucosal sites, and may 
also promote epithelial wound repair22. Lastly, the formyl peptide receptors (FPRs) serve as receptors to ANXA1. 
These FPRs may also function as HIV co-receptors for virus entry23, transmission and infection at epithelial sur-
faces and within tissue reservoirs of HIV-124. Thus, ANXA1 may compete for the same FPR binding site on HIV 
envelope molecules25,26.
We sought to investigate changes in ANXA1 expression in both peripheral and gut mucosal compartments 
during the course of SIV infection and disease progression. Our data showed divergent ANXA1 gene expression 
patterns in peripheral blood and gut mucosa in vivo during primary acute and chronic stages of viral infection, 
which may be associated with chronic SIV-infection induced immune activation. Further, expression of ANXA1 
was negatively correlated with pro-inflammatory cytokines and positively associated with anti-inflammatory 
response, which was corroborated by exogenous ANXA1 stimulation of peripheral and gut mucosal immune 
cells, suggesting that the endogenous ANXA1 signaling may be dysfunctional during SIV infection. Collectively, 
our data suggest that dysfunctional ANXA1 expression and signaling may not only impact the immune activation 
in periphery, but also may impair the gut immune responses, consequently leading to SIV disease progression.
Results
ANXA1 is differentially expressed in PBMC and gut mucosa during SIV infection. ANXA1 gene 
expression was analyzed in both peripheral blood and gut mucosal compartments at pre-infection time point and 
at 2, 10 and 26 weeks following SIV infection. In the early infection and during transition from acute to chronic 
stage of infection (2–10wks), the ANXA1 expression was up regulated in peripheral blood of SIV-infected ani-
mals (Fig. 1A). In contrast, a striking reduction of ANXA1 expression was seen in the gut mucosa at all time 
points during SIV infection (fold change average, FC = − 4.5) (Fig. 1B), indicating that SIV infection led to differ-
ential systemic and mucosal modulation of ANXA1 expression during early stages of infection. During chronic 
SIV infection (26wk), the ANXA1 expression remained significantly increased in peripheral blood (FC = + 4.2, 
p < 0.05), as shown in Fig. 1A, and this data was further supported by our previous study of gene expression pro-
filing in SIV infection using microarray analysis5. However, in the gut ANXA1 expression was back to normal at 
26wk following SIV infection when compared to uninfected controls (FC = +0.5; 26wk vs 2wk, p = 0.009; 26wk 
vs 10wk, p = 0.002) (Fig. 1B). Together, these data suggested a differential expression profile of ANXA1 between 
the peripheral blood and the gut both in acute and chronic SIV infections. Dampening the ANXA1 expression in 
the gut may be a result of the early and rapid loss of CD4+ T cells in this compartment compared to the blood3.
Increased ANXA1 expression in peripheral blood is correlated with immune activation and reservoir 
establishment. It is well established that HLA-DR expression levels on CD4+ T cells are correlated with 
changes in CD8+ T lymphocytes, plasma HIV antigen loads and the disease progression27. Recent study indicated 
that, among all other immune activation markers, only HLA-DR/DP/DQ(+ ) expression in CD8+ T cells was 
associated with persistent HIV infection as well as with HIV reservoir establishment during suppressive ART28. 
To this end, we assessed the percentages of CD4+ and CD8+ T cells expressing HLA-DR by flow cytometry. As 
expected, in the peripheral blood the number of HLA-DR positive CD4+ and CD8+ T-cells increased during 
Figure 1. Differential ANXA1 expression in blood and gut throughout the SIV infection. Relative 
expression of ANXA1 in PBMCs (A) and jejunum biopsy (B) after 2, 10 and 26 weeks of inoculation of Rhesus 
macaques with pathogenic doses of SIVMac251. Data are presented as fold change of infected versus uninfected 
animal per dot, with a line representing the mean of the expression’s group. Statistical analysis: p values were 
obtained on a per group basis (* ) using the Mann-Whitney non-parametric test (when comparing different 
time points).
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late chronic stage of infection and were coincident with immune activation. Importantly, ANXA1 expression 
in PBMCs presented significant positive correlation with cellular activation, revealing a similar dynamics of 
HLA-DR expression in both cell types (Fig. 2A,B), suggesting that expression of ANXA1 may be linked with 
reservoir establishment in vivo.
The gradual increase of ANXA1 expression during SIV infection may have impaired proper 
inflammatory responses in the peripheral blood. Due to the increased ANXA1 gene expression in 
PBMC and its association with immune activation, we performed additional assessments of specific cytokines 
and signaling molecules during SIV infection. During early infection (2wk), expression of pro-inflammatory 
cytokines IFN-γ , TNF-α , IL-17, IL-18, IL-22 (Th1 and Th17 responses) was negatively correlated with 
ANXA1 expression. At the disease transition (10wk), ANXA1 expression was positively correlated with IL-6/
STAT3/SOCS3 signaling, and in the chronic stage (26wk), expression of ANXA1 was positively correlated 
with anti-inflammatory cytokines IL-10 and TGF-β (Th2/Treg) in the peripheral blood (Figs 3A–C and 4A). 
Considering these results, we believe that the gradual increase of ANXA1 expression during SIV infection may 
have impaired proper inflammatory responses in the peripheral blood, facilitating disease progression.
ANXA1 expression in the gut mucosa parallels with an anti-inflammatory cytokine IL-10 
expression. To determine whether the ANXA1 expression correlates with changes in the cytokine expression 
patterns in the gut mucosa, we measured transcript levels of several cytokines in the gut mucosa during the course 
of SIV infection. We found a trend of increased expression of pro-inflammatory cytokines (IFN-γ , TNF-α , IL-6) 
in the gut mucosal compartments during primary SIV infection. Unlike the tendency of remaining elevated in 
the peripheral blood samples, the expression of IFN-γ and TNF-α were significantly decreased in the gut mucosa 
during chronic SIV infection. Contrarily, the expression of anti-inflammatory cytokines (IL-10) showed signifi-
cant increase in the gut when infection transited from acute to chronic infection (Fig. 4B). Divergence in the mag-
nitude of increased pro-inflammatory cytokines in the gut mucosa compared to the peripheral blood during SIV 
infection may have potentially limited the damage to the tissue microenvironment, and may also have contrib-
uted to the incomplete clearance of the virus, which is corroborated by our previous results shown elsewhere15.
Differential cytokine induction between peripheral blood and the gut mucosa stimulated by 
with Ac2–26 peptide in vitro. In order to exert its anti-inflammatory action and impact the disease pro-
cess, ANXA1 needs to be secreted to induce its signaling pathway6. However, based on its divergent expression 
profile between gut mucosa and PBMC, we hypothesized that the secretion and signaling of ANXA1 may be 
Figure 2. Increased systemic T cell activation correlates with ANXA1 expression. (A) Percentage of positive 
cells for HLA-DR amongst total CD4+ and CD8+ T cells from peripheral blood obtained at the indicated times 
before and after SIV infection (2, 10, 26 weeks). (B) Association of ANXA1 relative expression to the degree 
of systemic immune activation, as measured by percentage of the activated CD3+ CD4+ DR+ (R = 0.49) and 
CD3+ CD8+ DR+ (R = 0.47) T cells in the peripheral blood along the course of infection. In (A) data are 
represented as mean ± SEM. Statistical analysis: p values were obtained on a per group basis (* ) using the Mann-
Whitney nonparametric test (when comparing different time points). * p value < 0.05 and * * p value < 0.01 vs 
early times before and after infection. In (B) Spearman’s rank test was used to determine correlations between 
variables. Both correlations presented p value < 0.05.
www.nature.com/scientificreports/
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dysfunctional in both compartments. To investigate exogenous ANXA1 signaling, we stimulated PBMC and 
LPL cells from chronically SIV-infected rhesus macaques and SIV-negative healthy controls with the N-terminal 
peptide of ANXA1 (Ac2–26), and cytokine gene expression profiles were assessed. In PBMCs from SIV infected 
animals, IL-10 and TGF-β levels were induced, while TNF-α , IFN-γ and IL-6 levels were suppressed compared 
to PBMCs from SIV-negative controls (Fig. 4C). Similarly as in PBMCs, IL-10 was induced by ANXA1 in LPLs 
from gut mucosa of SIV-infected animals; in contrast to PBMCs, TNF-α and IL-6 were induced following Ac2–26 
stimulation (Fig. 4D). These findings reflect the divergent expression of ANXA1 in gut versus in PBMCs during 
SIV infection (Fig. 1), suggesting that SIV infection induced aberrant ANXA1 expression dampens gut immune 
response, which may be responsible for elevated immune activation in peripheral blood but immune anergy in 
the gut mucosa (Fig. 2), which is corroborated by our recent findings showing that gut immune responses are 
massively dampened at chronic stages of the SIV infection15.
Increased ANXA1 expression and systemic activation were negatively correlated with viral load 
and CD4+ T cell counts. The positive correlation between ANXA1 and HLA-DR were discordant from the 
expected positive association with CD4 counts and viral loads in both compartments, demonstrating contrasting 
dynamics in peripheral blood and gut mucosal compartments (Fig. 5). In fact, plasma viral load and CD4+ T cell 
counts declined throughout the infection, accompanied with increased ANXA1 expression in PBMCs and in the 
gut. Although ANXA1 acts as an anti-inflammatory mediator, the expression levels gradually increased during 
disease progression (Fig. 5A). These findings were further supported by a negative association between CCR5 
and ANXA1 expression in PBMC, showing that the higher ANXA1 levels, the lower the virus co-receptor expres-
sion (Fig. 5C), but this was not found in the intestine (data not shown). Despite a trend of decreased viral loads 
compared to those in the primary viral infection during chronic SIV infection, viral loads persisted (Fig. 5D) 
and depletion of CD4+ T cells was observed the gut mucosa (Fig. 5E). These changes correlated with increased 
ANXA1 expression. The increased ANXA1 expression was expected to counteract the chronic activation, which 
could contribute to the CD4+ T cell survival; however, in the gut ANXA1 expression was dampened, which 
could explain an inverse correlation between ANXA1 and CD4+ T cell counts, particularly the gut CD4+ T 
cell depletion during disease progression (Fig. 5B). Taken together, this further supports our hypothesis that the 
anti-inflammatory ANXA1 signaling is dysfunctional in SIV infection, and aberrant ANXA1 may be associated 
with systemic immune activation in peripheral blood but immune anergic in the gut.
Figure 3. Increased expression of systemic ANXA1 is associated with an anti-inflammatory profile and 
the IL-6 pathway in the peripheral blood. Plots present tendency lines and the association between ANXA1 
and cytokines expression along the SIV infection (2, 10, 26wk), demonstrating the systemic immune activation 
leading to an anti-inflammatory profile. Spearman’s rank test was used to determine correlations between 
ANXA1 and cytokines with p value < 0.05.
www.nature.com/scientificreports/
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Discussion
The systemic activation29 and gut immune dysfunction4 are two paradoxical hallmarks of SIV infection and 
AIDS, which have not been well understood. Most of our understanding of chronic immune activation is based 
on the factors or mechanisms that are pro-inflammatory. However, the balance between the inflammatory and 
anti-inflammatory mechanisms in the gut mucosa is critical for providing the immune defense while maintaining 
the integrity and function of the gut microenvironment. We hypothesized that mediators that intersect inflamma-
tory and anti-inflammatory mechanisms may be dysfunctional in the peripheral and gut mucosal compartments. 
Our investigation identified the ANXA1 protein as a potential mediator in these compartments for many reasons, 
which are explored herein.
We previously reported that ANXA1 expression was altered in the gut of SIV-infected macaques5. This highly 
active mediator is known to cause rapid resolution of inflammation6–9. However, to exert its anti-inflammatory 
action, ANXA1 needs to be secreted to trigger its signaling pathway6, which is involved in a broad range of biolog-
ical activities and control of several genes, including transcription factors and signaling molecules30,31. Signaling 
through ANXA1 binding to FPR2 receptor involves transient phosphorylation of ERK1, ERK2, AKT and JAK32,33. 
The ERK and AKT activation in T cells leads to cell proliferation, whereas ERK and JAK activation leads to a loss 
of cell adhesion to neutrophils, inhibition of IL-6 signaling and the release of TNF-α from endotoxin-challenged 
monocytes34, resulting in an anti-inflammatory effect. On the other hand, ANXA1 receptor FPR2 also serves as 
co-receptors for the HIV/SIV gp12035 and for a chemotactic peptide of the HIV-1 gp41 ectodomain24. Our study 
is the first to describe changes in the endogenous ANXA1 expression in PBMC and gut mucosa of SIV infected 
macaques showing a discordant expression between these two compartments. Importantly, striking alterations in 
expression pattern of major cytokines (IL-10, TGF-β , TNF-α and IL-6) were detected following exogenous stim-
uli with the ANXA1 N-terminal peptide, Ac2–26, resulting in reduced inflammatory response in the peripheral 
blood cells while reactivation of the gut immune cell response. These findings led us to propose that endoge-
nous ANXA1 signaling is dysfunctional in both PBMC and gut mucosa during SIV infection, and may be a link 
between systemic chronic activation and impaired gut immune responses.
Interestingly, we found a positive correlation between HLA-DR+ T cell percentages and ANXA1 levels in 
PBMC. Up-regulation of ANXA1 expression in T cells following activation and differentiation7 is possibly playing 
a homeostatic regulatory role in mature T cells by modulating the strength of TCR signaling33. In pathological 
Figure 4. Cytokine expression profiles of PBMCs (A,C) and LPLs (B,D) from SIV-infected and non-infected 
animals, according to the endogenous ANXA1 expression (A,B) and the exogenous stimuli of the Ac2–26 
ANXA1 N-terminal peptide (C,D). Relative gene expression of anti-inflammatory (IL-10, TGF-β ) and pro-
inflammatory (TNF-α , IFN-γ , IL-6) cytokines, in comparison to the endogenous ANXA1 expression profile 
in both PBMCs (A) and LPLs (B) along the time course of the SIV infection. Cytokines’ expression profiles 
were also recorded after Ac2–26 peptide stimuli of both PBMCs (C) and LPLs (D). Data are represented as 
mean ± SEM and are presented as fold change of infected versus uninfected animals. Statistical analysis: p values 
were obtained on a per group basis (* ) using the Mann-Whitney nonparametric test, when comparing different 
time points for (A,B) (* p < 0.05 and * * p < 0.01 before and after infection), and the Student T test for (C,D) 
(p < 0.05).
www.nature.com/scientificreports/
6Scientific RepoRts | 6:31157 | DOI: 10.1038/srep31157
conditions, the increased expression of endogenous ANXA1 might contribute to the basal hyper-activated state 
and to the up-regulation of transcription factors that modulate several inflammatory genes16. Consequently, in 
SIV/HIV infection, the enhanced ANXA1 expression in peripheral blood may provide T cells with positive sig-
nals for TCR-induced apoptosis36, or could simply be triggered to counteract the active systemic inflammation 
with its potent anti-inflammatory role. Paradoxically, since HIV replicates most efficiently in activated CD4+ T 
lymphocytes37, the chronic immune activation seems to be important for maintaining virus reservoirs by render-
ing cells competent for viral replication. Such mechanism is closely related to immune exhaustion, followed by a 
massive depletion of CD4+ T cells and disease progression38,39. We have consistently found a negative correlation 
between ANXA1 transcript levels and CD4+ T cell counts during chronic SIV infection (26 wks), suggest a puta-
tive role of ANXA1 in CD4+ T cell apoptosis as a clearance modulator, probably preventing further activation. 
As HLA-DR was recently identified the only immune activation marker associated with HIV reservoir in the 
patients under suppressive ART28, we only focused on expression of HLA-DR in T cells as an immune activation 
marker. Our findings that positive correlation of ANXA1 expression with HLD-DR in both CD4+ and CD8+ T 
cells indicated that ANXA1 could potentially contribute to SIV reservoir establishment (Fig. 2).
We found a significant negative correlation of ANXA1 expression with several pro-inflammatory cytokines 
and a positive correlation with anti-inflammatory cytokines, such IL-10 and TGF-β , in PBMC of SIV-infected 
animals, which are associated with immune dysregulation in HIV and considered as negative effects of the infec-
tion40. But, the low levels of TGF-β and constant release of circulating IL-6 of SIV-infected animals may have 
compromised the necessary balance between iTregs and Th17 response41. It is also possible that the high levels 
of ANXA1 expression in peripheral blood may have contributed to diminish transcription of pro-inflammatory 
cytokines. This could promote a transition from Th1 to Th2 T cell response, leading to a defective T-cell acti-
vation, and consequently to disease progression. This has been previously corroborated42 by the findings from 
the modulation of ANXA1 in the ANXA1-knockout mouse model43, in vitro cell culture stimulations with the 
ANXA1 N-terminal peptide (Ac2–26)44, and with glucocorticoids45. Our data also revealed a significant positive 
correlation between ANXA1 and IL-6 expression and its signaling pathway in PBMC, with up-regulation of 
STAT3 and down-regulation of SOCS3, but not in the gut mucosa. Therefore, IL-6 is evidently a key molecule 
in SIV infection, since circulating IL-6 levels consistently correlate with residual HIV viremia and markers of 
immune dysfunction in HIV infection46. Some of these findings may be explained by the conversion of IL-6 into 
an IL-10-like anti-inflammatory response due to the lack of SOCS3 expression in LPS-stimulated macrophages47.
Figure 5. Plasma viral load, CCR5 and CD4 T cell counts correlate to ANXA1 expression in the blood. 
Kinetics of plasma viral load ( ) and relative ANXA1 expression ( ) in PBMCs (A) and jejunum (D) obtained at 
the indicated times after SIV infection (2, 10, 26 weeks). Kinetics of CD4+ T cell counts (%) and relative ANXA1 
expression in the peripheral blood (B) and jejunum (E) as a function of time after infection. (C) Correlation 
between the relative CCR5 and ANXA1 expression in PBMCs. In (A,B) data are presented as mean ± SEM. In  
(C) Spearman’s rank test was used to determine correlation between variables, which presented a moderate 
positive R = 0.38, p value < 0.05.
www.nature.com/scientificreports/
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The ANXA1 expression was suppressed in the intestine during the initial and transitional stages of SIV infection. 
Since the major source of ANXA1 in the mucosa are epithelial cells48, such down-regulation could be a conse-
quence of the rapid disruption of tissue integrity probably caused by SIV exposure, as previously demonstrated 
in HIV infection14. Conversely, we found in data from previous microarray analyses of Sooty mangabeys that 
no changes in ANXA1 expression were observed in the gut of this natural hosts of non-pathogenic SIV infec-
tions, which do not present severe mucosal CD4 T cell depletion49 or tissue damage. Interestingly, in rhesus 
macaques, the concurrent down-regulation of ANXA1 expression in the gut during acute and chronic infections 
was followed by an overexpression of TNF-α and IFN-γ . These events may also be linked to tissue injury at early 
stages due to excessive inflammation without a counteracting anti-inflammatory response, as also evidenced 
by down-regulation of IL-10 and TGF-β , which as well disrupt the gut regenerative capacity, resulting in loss of 
mucosal integrity, a mechanism that was not previously identified, but with potential to contribute to the chronic 
inflammation. This injury may have triggered an enhanced local inflammatory reaction in the acute stage5,50 fol-
lowed by an impaired immune response in the chronic stage, probably due to the deprivation of sufficient CD4+ 
T cells51, which has led to the massive dampening of pattern recognition receptors expression detected in the gut 
mucosa, despite the presence of detectable viral loads15, leading to an anergic state in the chronic stage. The major 
challenge in restoring CD4+ T cells may stem from the inability of the host to repair and regenerate the mucosal 
damage caused by the virus50, which is corroborated by the absence of Annexin A1 in the gut, with direct implica-
tions in wound healing, especially in intestinal inflammation and injury21. Decreased ANXA1 expression in SIV+ 
animals during disease progression as described here may induce an inadequate response to bacterial infection52, 
phagocytosis signaling53, and Th1-driven responses33,54.
The negative effect of the endogenous ANXA1 suppression is further evidenced by the compensatory stim-
uli with exogenous recombinant ANXA1 that resulted in IL-10 release and IL-12 inhibition in LPS-activated 
macrophages55 and also by its putative protective and reparative properties of the intestinal mucosal epithelium 
against acute injuries21. The loss of ANXA1 expression in the gut tissue in SIV infection was associated with 
chronic infection and an anergic phase15, similar to an anti-inflammatory scenario, in which cytokines’ release 
was maintained at basal levels (TNF-α , IL-10, IFN-γ or TGF-β ), except for IL-6 that remained highly expressed, 
which may have caused a progressive mucosal immune dysfunction, a key feature of the HIV/SIV-associated 
immune deficiency4. The Th17 signaling was also affected as shown by progressive loss of IL-17 and IL-22 as 
ANXA1 expression increased in the periphery. However, the Th17 response is both permissive and inhibitory 
of the Th1 response, probably at different phases of the inflammatory process56. It has been shown that Th17 
cells induced in the presence of IL-1β have a unique messenger RNA profile and an increased capacity to induce 
inflammation57, suggesting that not all Th17 cells are equal. It is interesting to observe that, at early infection, we 
have seen variable expression of IL-17 coinciding with lower levels of ANXA1, and these results are corroborated 
by minimal CD4+ Th17 dysregulation in the blood until later stage of HIV infection, while gastrointestinal 
Th17 depletion was apparent much earlier, along with increased plasma markers of microbial translocation58. 
Meanwhile, lower levels of ANXA1 were maintained in all stages when compared to SIV negative animals, and 
only reached basal levels in the advanced chronic stage.
Increased plasma IL-6 levels have been associated with HIV-1 disease progression risk59, and its increased 
production in HIV-infected patients at a late stage of the infection did not stimulate HIV replication in vivo, 
but might contribute to metabolic and immunological disturbances associated with the disease60. However, the 
route by which IL-6 comes to be expressed to high levels in blood during HIV infection is still unclear. IL-6 is 
produced by monocytes and highly induced in vitro by HIV infection61, and may also be involved in disease 
progression by promoting T-cell proliferation62, because activated T cells replicate HIV in preference to resting T 
cells63. However, LPS-stimulated macrophages infected with HIV were not capable of inducing IL-6 production, 
and its expression was not increased in lymph node histocultures obtained from HIV-1-infected subjects nor 
after productive HIV-1 infection of colonic or lymph node histocultures ex vivo59. Interestingly, IL-6 can reacti-
vate provirus in HIV-1 infected macrophages64. This controversial role of IL-6, and divergent behavior between 
monocytes and macrophages during HIV infection may be due to the persistent defect of infected cells, which is 
corroborated by our findings of ANXA1 signaling dysfunction in both compartments.
Our studies of ex vivo stimulations of PBMCs from SIV infected and SIV-negative macaques with Ac2–
26 demonstrated a switch in the immune response of SIV-infected animals from pro-inflammatory to an 
anti-inflammatory profile, characterized by elevated levels of IL-10 and reduced levels of IL-6, TNF-α and IFN-γ . 
However, following the divergent behavior between compartments, the gut presented an opposite response, with 
increased response of IL-10, TNF-α , and IL-6. However, it is important to emphasize that IL-10 levels remained 
elevated in the blood but presented very low levels in the gut during chronic infection when compared to SIV neg-
ative animals. So, the notion that IL-10 signaling presents a negative effect in the disease is still unclear, because its 
impact in the virus infection in vivo is complex and dependent on disease stage65. It has also been argued that the 
interplay of Tregs with monocytes, with upregulation of the IL-10 pathway in the blood might lead to increased 
disease progression by limiting the host immune responses and impairing pathogen clearance, but it may also 
function by moderating inflammation, with the benefit of limiting immune-mediated damage to the host65. On 
the other hand, the strong activation of IL-6 in Ac2–26-stimulated LPLs suggests that this cytokine may play a 
key role in mucosal protection, since its absence was associated with marked infection-induced apoptosis in the 
colonic epithelium and subsequent ulcerations in a rat model66. Interestingly, the massively dampened immune 
response in the gut during chronic infection15 was reactivated by the Ac2–26-stimulated LPLs, as shown by 
increased levels of TNF-α , and most important, IL-10 and TGF-β expression presented only a small increase, but 
were maintained in homeostasis, without inhibiting the inflammatory response, which may be considered as ben-
eficial. Therefore, the ability of the exogenous ANXA1 peptide to shape a pro-inflammatory response in the gut 
and an anti-inflammatory response in PBMC, support the notion that ANXA1 is a homeostatic molecule in both 
microenvironments and its signaling may be dysfunctional, but the causative mechanism must still be determined.
www.nature.com/scientificreports/
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In progressive HIV/SIV infections, the level of immune activation is a consistent predictor of disease pro-
gression as compared to either plasma viral load or peripheral CD4+ T-cell counts67. Additionally, our recent 
findings showed that the gut epithelium was the initial target of viral pathogenesis, as evidenced by impaired 
expression and disorganization of epithelial tight junction proteins, which were correlated to increased expression 
of interleukin-1β 68. In fact, the ANXA1 expression seems to be absent or insufficient, which is responsible to dif-
ferentially activate several tissue specific cells, which lose the ability of regulating the anti- and pro-inflammatory 
molecules, such as IL-10, IL-6 and others. Based on our findings of in vitro stimulations, we propose that proper 
ANXA1 expression and signaling may lead to the recovery of the gut immune response and reduce systemic 
activation. Whether viral gp120 competes for the same ANXA1 receptor and impairs its signaling pathway, or if 
there are other molecular events modifying the ANXA1 signaling during SIV/HIV infection still remain to be 
elucidated.
In summary, our data reinforce the importance of understanding the crosstalk between systemic and mucosal 
immunity through ANXA1 signaling during SIV infection in vivo, which apparently acts like a double-edged 
sword in both processes.
Materials and Methods
Animals and Samples. Nonhuman primate studies were performed in accordance with the recommended 
guidelines of the Public Health Services Policy on Humane Care and Use of Laboratory Animals. Sixty-five col-
ony-bred rhesus macaques (Macaca mulatta) were housed at the California National Primate Research Center. 
Procedures and sample collections were performed according to the protocols approved by the Institutional 
Animal Care and Use Committee at the University of California, Davis. Anesthetics and analgesics were used 
during the procedures to minimize pain in animals. Environmental enrichment and feeding were provided 
in accordance with the recommended guidelines. Animals were euthanized in accordance with the American 
Veterinary Medical Association Guidelines for the Euthanasia of Animals.
Samples from 12 healthy, SIV-negative animals served as negative controls. Fifty-three animals were intrave-
nously inoculated with animal infectious doses of pathogenic SIVmac251 and were euthanized during primary 
SIV infection (2week-wk) (n = 16), chronic infection (10wk) (n = 22), and advanced infection with simian AIDS 
(26wk) (n = 15). A cross-sectional study was carried on with jejunum biopsy samples collected by upper endos-
copy and peripheral blood samples by venipuncture in each infection time point. Peripheral blood and intestinal 
tissue samples were isolated and evaluated as previously described69.
Measurement of Viral Load and Host Gene Expression. Total RNA from PBMC and jejunum biopsy 
samples were isolated using Qiagen RNeasy Plus Mini Kit in accordance with the manufacturer’s protocol 
(Qiagen, Valencia, CA). Viral load and host gene expression analyses were performed by quantitative real-time 
PCR. Briefly, specific primers and probes of the SIV RNA sequence and human cytokines’ gene sequences 
(ANXA1, CCR5, STAT3, SOCS3, IL10, TGF-β , TNF-α , IFN-γ , IL-6, IL-12, IL-17, IL-18, IL-22), and their reac-
tion conditions are described elsewhere70. Fluorescent signals were detected with an ABI Prism 7700 sequence 
detector (PE Applied Biosystems). Data were captured and analyzed with Sequence Detector software (SDS). 
Viral copy number in PBMC was determined by plotting CT values against a standard curve. For jejunum sam-
ples, relative SIV viral RNA loads were calculated utilizing internal normalization of CT values with housekeeping 
genes (glyceraldehyde-3-phosphate dehydrogenase, GAPDH; and/or CCR5). For host gene expression, internal 
normalization of CT values was performed based on GAPDH for each animal, and differential gene expression 
was calculated by using CT values obtained for each of the SIV-infected animals divided by the mean CT values 
from four uninfected controls.
Flow Cytometry. For immunophenotyping of the cells, rhesus-compatible human antibodies were used to 
detect CD3 (BD Biosciences, clone SP-34-2, San Jose, CA), CD4 (Ebioscience, clone OKT4, San Diego, CA), CD8 
(Invitrogen, clone RPA-T8) and HLA-DR (Biolegend, clone L243). To detect cell viability, cells were stained with 
Amcyan LIVE amine dye (Invitrogen, Carlsbad, CA). Multicolor immunophenotyping of cells was performed on 
a modified BD LSRII with collection of 1,000,000 events. Flow cytometric analysis was performed using FlowJo 
version 7.3 (Treestar, Stanford, CA).
In vitro Stimulations with ANXA1 Peptide. Annexin-1N-terminal peptide Ac2–26 (GenScript, USA) 
was used to stimulate primary peripheral blood mononuclear cells (PBMC) and lamina propria lymphocytes 
(LPL) from four rhesus macaques with chronic SIV infection and from four uninfected controls. PBMCs and 
LPLs were isolated as previously described69, and incubated at 37 °C for 1 hour in complete RPMI. Cells were cen-
trifuged at 1800 rpm. Aliquots of 1 × 105 cells were added to a 100 μ l well, and 100 μ M Ac2–26 solution was added 
to both experimental cells and control medium, in duplicates, followed by incubation at 37 °C for 30 minutes. 
After stimulations, cells were pipetted into 1.5-ml tubes, centrifuged at 1800 rpm, and medium was discarded. 
Cells were cryopreserved at − 80 °C until RNA extraction. Gene expression was carried out as described before.
Statistical Analysis. Comparisons between two animal groups or different tissues were performed using 
two-tailed Mann-Whitney’s U-test or Student’s T test. Pearson’s Correlation Test was used to perform correlation 
analyses among variables. For correlations, including the PBMC and jejunum tissue viral load, we used the indi-
vidual viral RNA copy numbers per mL of plasma of each animal at the respective time points when the assay 
was performed. All statistical analyses were performed by GraphPad Prism 5.0 software (GraphPad Software, San 
Diego, USA). Data was considered as statistically significant when p < 0.05.
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